NL-OMON35986已完成不适用
AN OPEN-LABEL STUDY IN HEALTHY MALE SUBJECTS TO ASSESS THE ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION OF [14C]-LABELED BIA 9-1067 AND METABOLITES FOLLOWING A SINGLE-DOSE ORAL ADMINISTRATION - BIA 9-1067 ADME study
Bial Portela & Ca.0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy male subjects
- •Age: 18-55 years
- •BMI: 18.0 - 30.0 kg/m2
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study or in case of donating more than 1 liter of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
A single-site, open-label study in healthy male subjects to compare rotigotine saliva and plasma concentrations in steady-state after multiple-dose application of rotigotine transdermal patchrestless legs10028037Parkinson's DiseaseNL-OMON35531CB Pharma14
未知
Unknown
Administration study to healthy adult male as part of reserch toward the development of detection method for testosterone doping-JPRN-jRCT1080223310SI Medience Corporation10
未知
Unknown
Administration study to healthy adult male as part of reserach toward the development of detection method for testosterone doping-JPRN-jRCT1080222855SI Medience Corporation8
已完成
1 期
Open-Label Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Risperidone to Risperidone Implant (DLP-114)SchizophreniaACTRN12617001251314Delpor Australia Pty Ltd17
已完成
不适用
Single-center, open-label study in healthy male subjects to evaluate the absolute bioavailability of a 10 mg oral dose of vericiguat (BAY 1021189) (as IR tablets following a high-fat, high-calorie meal) in comparison to an intravenous, 14C-labeled micro-dose (20 µg) of vericiguat10019280heart failureNL-OMON42434Bayer HealthCare AG, Clinical Sciences10